Roberto Ferrara, Medical Oncology Researcher at Vita-Salute San Raffaele University, shared on X:
“We should tailor treatments combined to ICI not only according to markers for new drugs but also according to markers of primary/acquired resistance to ICI.
In patients with PR to chemo-ICI, the worse OS with PARPi suggests a detrimental effect of PARPi on acquired resistance to ICI.”
More Posts Featuring Roberto Ferrara.